| Bioactivity | Blonanserin (AD-5423) is a potent and orally active 5-HT2A (Ki=0.812 nM) and dopamine D2 receptor (Ki =0.142 nM) antagonist. Blonanserin is usually acts as an atypical antipsychotic agent and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension[1]. | ||||||||||||
| Invitro | Blonanserin exerts some blockade of α1-adrenergic receptors (Ki=26.7 nM) and also shows significant affinity for the D3 receptor (Ki=0.494 nM). Blonanserin possesses low affinity for the sigma receptor (IC50=286 nM), but lacks significant affinity for numerous other sites including the 5-HT1A, 5-HT3, D1, α2-adrenergic, β-adrenergic, H1, and mACh receptors and the monoamine transporters[1]. | ||||||||||||
| In Vivo | Blonanserin (oral gavage; 1 mg/kg; 14 days) significantly ameliorates the social deficit observed in PCP-administered mice and inhibits the decrease in the levels of Ser897-phosphorylation, but preatment with blonanserin does not affect the social behaviors in saline-administered mice[2]. Animal Model: | ||||||||||||
| Name | Blonanserin | ||||||||||||
| CAS | 132810-10-7 | ||||||||||||
| Formula | C23H30FN3 | ||||||||||||
| Molar Mass | 367.50 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Blonanserin [2]. Saori Takeuchi, et al. Blonanserin ameliorates social deficit through dopamine-D 3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia. Neurochem Int. 2019 Sep;128:127-134. |